Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | REN | P00797 | 1/20 | 0.38 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.37 |
| ▸ | NAAA | Q02083 | 2/20 | 0.34 |
| ▸ | BCHE | P06276 | 1/20 | 0.34 |
| ▸ | LTA4H | P09960 | 1/20 | 0.33 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.33 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.33 |
| ▸ | OPRL1 | P41146 | 2/20 | 0.33 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.33 |
| ▸ | DPP4 | P27487 | 1/20 | 0.33 |
| ▸ | CTSL | P07711 | 1/20 | 0.33 |
| ▸ | CTSB | P07858 | 1/20 | 0.33 |
| ▸ | CTSK | P43235 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20233717 | 0.84 | TDP1 (0.43) | RENGABRA5NAAALTA4H | |
| SCHEMBL20120315 | 0.82 | OPRK1 (0.41) | GABRA5NAAAOPRM1OPRL1SLC6A4 | |
| SCHEMBL20120314 | 0.82 | OPRK1 (0.41) | GABRA5NAAAOPRM1OPRL1SLC6A4 | |
| SCHEMBL20120673 | 0.81 | OPRK1 (0.37) | RENGABRA5NAAASLC6A4 | |
| SCHEMBL29547504 | 0.81 | OPRK1 (0.37) | RENGABRA5NAAASLC6A4 | |
| SCHEMBL20128967 | 0.78 | SLC6A4 (0.35) | RENGABRA5SLC6A4 | |
| SCHEMBL20128964 | 0.76 | ALDH1A1 (0.43) | BCHEOPRM1OPRL1DPP4CTSL | |
| SCHEMBL20120516 | 0.76 | NAAA (0.44) | RENGABRA5NAAALTA4H | |
| SCHEMBL1927115 | 0.75 | GABRA5 (0.44) | RENGABRA5NAAALTA4H | |
| SCHEMBL29457401 | 0.72 | GABRA5 (0.52) | GABRA5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11912699-B2 | Tau-protein targeting compounds and associated | ARVINAS OPERATIONS, INC. (US) | 2024-02-27 | — | — | US | disclosed |
| US-11912699-B2 | Tau-protein targeting compounds and associated | ARVINAS OPERATIONS, INC. (US) | 2024-02-27 | — | — | US | disclosed |
| US-20180125821-A1 | TAU-PROTEIN TARGETING PROTACS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. | 2018-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11912699-B2 | Tau-protein targeting compounds and associated | MAPT, VHL, CRBN | REN 3286/4885GABRA5 2135/4885NAAA 4529/4885 |
| US-20180125821-A1 | TAU-PROTEIN TARGETING PROTACS AND ASSOCIATED METHODS OF USE | CRBN, VHL, UBQLN2 | REN 3087/4885GABRA5 2124/4885NAAA 4503/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.